human embryonic kidney 293tt  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    ATCC human embryonic kidney 293tt
    nfGNPs inhibit HPV16 PsV pseudo-infection better than heparin. Inhibition of PsV pseudo-infection by nfGNPs, nfSNPs and heparin. Pseudo-infected <t>293TT</t> cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.
    Human Embryonic Kidney 293tt, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human embryonic kidney 293tt/product/ATCC
    Average 94 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    human embryonic kidney 293tt - by Bioz Stars, 2022-12
    94/100 stars

    Images

    1) Product Images from "Non-Functionalized Gold Nanoparticles Inhibit Human Papillomavirus (HPV) Infection"

    Article Title: Non-Functionalized Gold Nanoparticles Inhibit Human Papillomavirus (HPV) Infection

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms23147552

    nfGNPs inhibit HPV16 PsV pseudo-infection better than heparin. Inhibition of PsV pseudo-infection by nfGNPs, nfSNPs and heparin. Pseudo-infected 293TT cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.
    Figure Legend Snippet: nfGNPs inhibit HPV16 PsV pseudo-infection better than heparin. Inhibition of PsV pseudo-infection by nfGNPs, nfSNPs and heparin. Pseudo-infected 293TT cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.

    Techniques Used: Infection, Inhibition, Fluorescence, Flow Cytometry, Standard Deviation

    nfGNPs inhibit HPV16 PsV pseudo-infection. ( A ) Fluorescence microscopy of 293TT cells infected with PsV treated with nfGNPs. HPV16 PsV was incubated with increased concentrations of nfGNPs before 293TT cell infection. ( B ) Inhibition of PsV pseudo-infection by nfGNPs. Pseudo-infected 293TT cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.
    Figure Legend Snippet: nfGNPs inhibit HPV16 PsV pseudo-infection. ( A ) Fluorescence microscopy of 293TT cells infected with PsV treated with nfGNPs. HPV16 PsV was incubated with increased concentrations of nfGNPs before 293TT cell infection. ( B ) Inhibition of PsV pseudo-infection by nfGNPs. Pseudo-infected 293TT cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.

    Techniques Used: Infection, Fluorescence, Microscopy, Incubation, Inhibition, Flow Cytometry, Standard Deviation

    2) Product Images from "Antiviral Effects of Artesunate on JC Polyomavirus Replication in COS-7 Cells"

    Article Title: Antiviral Effects of Artesunate on JC Polyomavirus Replication in COS-7 Cells

    Journal: Antimicrobial Agents and Chemotherapy

    doi: 10.1128/AAC.03714-14

    Permissivity of COS-7, HEK 293TT, SVG-A, and M03.13 cells for JCPyV MAD-4. The cells were infected with JCPyV MAD-4 for 2 h before the inoculum was replaced with fresh medium. (A) Extra- and intracellular JCPyV DNAs were quantified by qPCR of supernatants
    Figure Legend Snippet: Permissivity of COS-7, HEK 293TT, SVG-A, and M03.13 cells for JCPyV MAD-4. The cells were infected with JCPyV MAD-4 for 2 h before the inoculum was replaced with fresh medium. (A) Extra- and intracellular JCPyV DNAs were quantified by qPCR of supernatants

    Techniques Used: Infection, Real-time Polymerase Chain Reaction

    3) Product Images from "Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs"

    Article Title: Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0050296

    Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.
    Figure Legend Snippet: Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.

    Techniques Used: Recombinant, Expressing, Generated, Amplification, Polymerase Chain Reaction, Western Blot, Infection, Marker

    4) Product Images from "Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs"

    Article Title: Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0050296

    Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.
    Figure Legend Snippet: Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.

    Techniques Used: Recombinant, Expressing, Generated, Amplification, Polymerase Chain Reaction, Western Blot, Infection, Marker

    5) Product Images from "Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs"

    Article Title: Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0050296

    Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.
    Figure Legend Snippet: Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.

    Techniques Used: Recombinant, Expressing, Generated, Amplification, Polymerase Chain Reaction, Western Blot, Infection, Marker

    6) Product Images from "Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs"

    Article Title: Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0050296

    Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.
    Figure Legend Snippet: Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.

    Techniques Used: Recombinant, Expressing, Generated, Amplification, Polymerase Chain Reaction, Western Blot, Infection, Marker

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    ATCC human embryonic kidney 293tt
    nfGNPs inhibit HPV16 PsV pseudo-infection better than heparin. Inhibition of PsV pseudo-infection by nfGNPs, nfSNPs and heparin. Pseudo-infected <t>293TT</t> cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.
    Human Embryonic Kidney 293tt, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human embryonic kidney 293tt/product/ATCC
    Average 94 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    human embryonic kidney 293tt - by Bioz Stars, 2022-12
    94/100 stars
      Buy from Supplier

    Image Search Results


    nfGNPs inhibit HPV16 PsV pseudo-infection better than heparin. Inhibition of PsV pseudo-infection by nfGNPs, nfSNPs and heparin. Pseudo-infected 293TT cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.

    Journal: International Journal of Molecular Sciences

    Article Title: Non-Functionalized Gold Nanoparticles Inhibit Human Papillomavirus (HPV) Infection

    doi: 10.3390/ijms23147552

    Figure Lengend Snippet: nfGNPs inhibit HPV16 PsV pseudo-infection better than heparin. Inhibition of PsV pseudo-infection by nfGNPs, nfSNPs and heparin. Pseudo-infected 293TT cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.

    Article Snippet: The human embryonic kidney 293TT (ATCC CRL-3467) cells were cultured in Gibco® Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 5% Gibco® fetal bovine serum (FBS) (Thermo Fisher Scientific), 100 IU/mL penicillin, 100 µg/mL streptomycin (PAA Laboratories Inc., Pasching, Austria) and 200 μg/mL Gibco® hygromycin (Thermo Fisher Scientific) at 37 °C and 5% CO2.

    Techniques: Infection, Inhibition, Fluorescence, Flow Cytometry, Standard Deviation

    nfGNPs inhibit HPV16 PsV pseudo-infection. ( A ) Fluorescence microscopy of 293TT cells infected with PsV treated with nfGNPs. HPV16 PsV was incubated with increased concentrations of nfGNPs before 293TT cell infection. ( B ) Inhibition of PsV pseudo-infection by nfGNPs. Pseudo-infected 293TT cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.

    Journal: International Journal of Molecular Sciences

    Article Title: Non-Functionalized Gold Nanoparticles Inhibit Human Papillomavirus (HPV) Infection

    doi: 10.3390/ijms23147552

    Figure Lengend Snippet: nfGNPs inhibit HPV16 PsV pseudo-infection. ( A ) Fluorescence microscopy of 293TT cells infected with PsV treated with nfGNPs. HPV16 PsV was incubated with increased concentrations of nfGNPs before 293TT cell infection. ( B ) Inhibition of PsV pseudo-infection by nfGNPs. Pseudo-infected 293TT cell fluorescence was quantified by flow cytometry and plotted relative to the non-treated PsV control. The graphs represent the mean and standard deviation of three independent experiments.

    Article Snippet: The human embryonic kidney 293TT (ATCC CRL-3467) cells were cultured in Gibco® Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 5% Gibco® fetal bovine serum (FBS) (Thermo Fisher Scientific), 100 IU/mL penicillin, 100 µg/mL streptomycin (PAA Laboratories Inc., Pasching, Austria) and 200 μg/mL Gibco® hygromycin (Thermo Fisher Scientific) at 37 °C and 5% CO2.

    Techniques: Infection, Fluorescence, Microscopy, Incubation, Inhibition, Flow Cytometry, Standard Deviation

    Permissivity of COS-7, HEK 293TT, SVG-A, and M03.13 cells for JCPyV MAD-4. The cells were infected with JCPyV MAD-4 for 2 h before the inoculum was replaced with fresh medium. (A) Extra- and intracellular JCPyV DNAs were quantified by qPCR of supernatants

    Journal: Antimicrobial Agents and Chemotherapy

    Article Title: Antiviral Effects of Artesunate on JC Polyomavirus Replication in COS-7 Cells

    doi: 10.1128/AAC.03714-14

    Figure Lengend Snippet: Permissivity of COS-7, HEK 293TT, SVG-A, and M03.13 cells for JCPyV MAD-4. The cells were infected with JCPyV MAD-4 for 2 h before the inoculum was replaced with fresh medium. (A) Extra- and intracellular JCPyV DNAs were quantified by qPCR of supernatants

    Article Snippet: In order to find the most permissive cell line for our JCPyV antiviral study, the replication of JCPyV MAD-4 was investigated in COS-7, HEK 293TT, SVG-A, and M03.13 cells.

    Techniques: Infection, Real-time Polymerase Chain Reaction

    Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.

    Journal: PLoS ONE

    Article Title: Immunogenicity of Bivalent Human Papillomavirus DNA Vaccine Using Human Endogenous Retrovirus Envelope-Coated Baculoviral Vectors in Mice and Pigs

    doi: 10.1371/journal.pone.0050296

    Figure Lengend Snippet: Characterization of recombinant baculovirus and expression of HPV16 or HPV18 L1. AcHERV-HP16L1 (A) and AcHERV-HP18L1 (B) were generated by amplification of HERV env and HPV L1 genes from viral DNA using specific PCR primers. Controls were prepared by omitting templates from the sample. M: 100-bp ladder; Lane 1: HERV env; Lane 2: HPV 16L1; Lane 3: HPV 18L1; Lane 4: Control. Western blotting was performed on extracts of HPV16 pseudovirus-, HPV18 pseudovirus-, AcHERV-HP16L1- or AcHERV-HP18L1-infected 293TT cells using anti-HPV16L1 (C), anti-HPV18L1 (D), and anti- ß-actin antibodies (E). M: protein marker; Lane 1: lysate from cells infected with HPV16 pseudovirus; Lane 2: lysate from cells infected with HPV18 pseudovirus; Lane 3: lysate from cells infected with AcHERV-HP16L1; Lane 4: lysate from cells infected with AcHERV-HP18L1; Lane 5: lysate from uninfected cells.

    Article Snippet: Three days after infection, 293TT cells were lysed by incubating with lysis buffer.

    Techniques: Recombinant, Expressing, Generated, Amplification, Polymerase Chain Reaction, Western Blot, Infection, Marker